Regenxbio (RGNX) Liabilities and Shareholders Equity (2014 - 2025)

Regenxbio's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $453.0 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 2.78% year-over-year to $453.0 million; the TTM figure through Dec 2025 stood at $2.1 billion (down 6.11% YoY), while the FY2025 annual figure was $453.0 million, down 2.78% from the prior year.
• Liabilities and Shareholders Equity was $453.0 million for Q4 2025 at Regenxbio, down from $525.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q4 2021 to a low of $453.0 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $709.9 million across 5 years, with a median of $658.1 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity surged 89.56% in 2021, then sank 31.12% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then declined by 25.19% to $833.3 million in 2022, then slumped by 31.12% to $574.0 million in 2023, then declined by 18.81% to $466.0 million in 2024, then retreated by 2.78% to $453.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $453.0 million (Q4 2025), $525.2 million (Q3 2025), and $581.0 million (Q2 2025), per Business Quant data.